Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oleylphosphocholine

Next Previous
Drug Profile

Oleylphosphocholine

Alternative Names: D-121; OIPC

Latest Information Update: 14 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Max Planck Innovation
  • Developer Oblita Therapeutics
  • Class Antiparasitics; Phospholipids; Quaternary ammonium compounds
  • Mechanism of Action Cell division inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leishmaniasis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chagas disease; Cryptosporidiosis; Leishmaniasis; Mycoses

Most Recent Events

  • 14 Nov 2023 Oleylphosphocholine is still in phase I trials for Mycoses, Leishmaniasis, Cryptosporidiosis and Chagas-disease in Belgium (PO) (Oblita Therapeutics pipeline, November 2023)
  • 21 Jun 2023 Phase-I clinical trials in Leishmaniasis in Germany (PO) (NCT06124144)
  • 28 Mar 2019 No recent reports of development identified for phase-I development in Chagas-disease in Belgium (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top